glp 1 agonist vs analog Comparing Ozempic, Wegovy and Other GLP-1 Drugs Comparison of GLP-1 receptor agonists
Description
2022;13 doi: 10.3389/fimmu.2022.997578
Barcelona, Spain) was used
Semaglutide is also approved to reduce CVD risk in patients with CVD and either obesity or overweight and in phase 3 clinical trials showed kidney and cardiovascular protection in patients with T2DM and albuminuric CKD (FLOW trial) as well as in persons without diabetes that had CVD and overweight/obesity (SELECT trial)
Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023
2012) Exenatide has 53% homology with GLP-1
The required information typically includes: Diagnosis: Documentation of the patients condition, such as type 2 diabetes, obesity, hypertension, or cardiovascular issues, that warrants the use of a GLP-1 medication
